Humacyte (HUMA) Capital Leases (2020 - 2026)
Humacyte (HUMA) posted quarterly Capital Leases of $27.6 million for Q1 2026, up 114.9% year-over-year from $12.8 million in Q1 2025, and up 2.33% quarter-over-quarter from $27.0 million in Q4 2025.
Humacyte (HUMA) Capital Leases (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Capital Leases for 7 consecutive years, with $27.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Leases rose 114.9% year-over-year to $27.6 million; the TTM figure through Mar 2026 stood at $27.6 million (up 114.9% YoY), while the FY2025 annual figure was $27.0 million, up 98.05% from the prior year.
- Capital Leases advanced to $27.6 million in Q1 2026 per HUMA's latest filing, from $27.0 million in the prior quarter.
- Across five years, Capital Leases topped out at $27.6 million in Q1 2026 and bottomed at $12.0 million in Q2 2025.
- Historically, Capital Leases has averaged $18.4 million across 5 years, with a median of $17.6 million in 2023.
- Annual changes were most pronounced in 2025 — Capital Leases retreated 20.45% — and 2026, when it surged 114.9%.
- Humacyte's Capital Leases stood at $18.9 million in 2022, then fell by 13.58% to $16.3 million in 2023, then declined by 16.41% to $13.6 million in 2024, then jumped by 98.05% to $27.0 million in 2025, then increased by 2.33% to $27.6 million in 2026.
- Business Quant data shows HUMA's Capital Leases at $27.6 million in Q1 2026, $27.0 million in Q4 2025, and $27.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Humacyte | 150.77 Mn | 150.77 Mn | -825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.34 Mn |
| Mar 31, 2026 | 27.60 Mn |
| Dec 31, 2025 | 26.97 Mn |
| Sep 30, 2025 | 27.16 Mn |
| Jun 30, 2025 | 12.03 Mn |
| Mar 31, 2025 | 12.84 Mn |
| Dec 31, 2024 | 13.62 Mn |
| Sep 30, 2024 | 14.38 Mn |
| Jun 30, 2024 | 15.12 Mn |
| Mar 31, 2024 | 15.85 Mn |
| Dec 31, 2023 | 16.29 Mn |
| Sep 30, 2023 | 16.96 Mn |
| Jun 30, 2023 | 17.61 Mn |
| Mar 31, 2023 | 18.25 Mn |
| Dec 31, 2022 | 18.85 Mn |
| Sep 30, 2022 | 19.44 Mn |
| Jun 30, 2022 | 20.02 Mn |
| Mar 31, 2022 | 20.58 Mn |
| Dec 31, 2021 | 21.11 Mn |
| Sep 30, 2021 | 21.63 Mn |